QIAGEN
Manchester, United Kingdom
NCT Number: NCT06824129
Performance evaluation of QIAstat-Dx cUTI Plus AMR Panel using the QIAstat-Dx® Analyzer to demonstrate that the QIAstat-Dx cUTI Plus AMR Panel achieves its intended performance during normal conditions of use by the intended user in the intended environment
This study is active but is not currently recruiting participants.
Notify MeAll sexes
Observational
Manchester, United Kingdom
The objective of the study is to demonstrate that the QIAstat-Dx cUTI Plus AMR Panel achieves its intended performance during normal conditions of use by the intended user in the intended environment.
The primary objective is to evaluate the performance of QIAstat-Dx cUTI Plus AMR Panel in comparison with the results obtained from the reference method.
The secondary objective of the study is to evaluate the safety ofQIAstat-Dx cUTI Plus AMR Panel with respect to users/operators.
The primary study endpoint will be the results for each analyte obtained from testing prospective specimens with QIAstat-Dx cUTI Plus AMR Panel and Reference Method. Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) will be determined
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 8 months
Positive percent agreement
Time frame: 8 months
Negative percent agreement
QIAGEN Gaithersburg, Inc
Industry
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR Panel on Patients Suspected of Complicated Urinary Tract Infection
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06672978
Acute Pyelonephritis, Complicated Urinary Tract Infection
Little Rock, Arkansas, United States
View Trial DetailsNCT04876131
Complicated Urinary Tract Infection, Infection
Adelaide, South Australia, Australia
View Trial DetailsNCT04979806
Acute Pyelonephritis, Complicated Urinary Tract Infection
Fort Myers, Florida, United States
View Trial DetailsNCT05905055
Acute Pyelonephritis, Complicated Intra-abdominal Infection
Changsha, China
View Trial Details